Clinical Study

Intravitreal Anti-Vegf For The Treatment Of Choroidal Neovascularization Secondary To Ocular Histoplasmosis: A Ten-Year Follow-Up

Posted Date: Apr 20, 2021

  • Investigator: Carl Noble
  • Specialties:
  • Type of Study: Observational/Survey

Purpose: Assess 10-year outcomes of intravitreal anti-VEGF injections (IVI) and verteporfin photodynamic therapy (PDT) for choroidal neovascularization (CNV) related to presumed ocular histoplasmosis syndrome (POHS). Methods: Retrospective, comparative case series of 113 eyes treated with either IVI or combination IVI/PDT for subfoveal or juxtafoveal CNV secondary to POHS from Jan. 2006 to Jan. 2021. Primary outcome, visual acuity (VA). Secondary outcomes, number of annual injections (NAI) and disease-free interval (DFI). Results: Mean follow-up of 13 years. Significant difference in logMAR VA was found in year 1, 0.26 vs 0.56 (P=0.02), for subfoveal CNV in IVI vs IVI/PDT respectively. Significantly fewer NAI for all CNVs in year 2, 1.36 vs 3.07 (P=0.001), and juxtafoveal CNVs in years 9, 1.8 vs 4.6 (P=0.01), and 10, 1.8 vs 4.1 (P=0.04), for IVI/PDT vs IVI respectively. DFI for juxtafoveal CNVs was significantly longer in year 9, 57.94 vs 29.94 mos (P=0.04), and year 10, 58.28 vs 21.78 mos (P=0.01), for IVI/PDT vs IVI respectively. Conclusion: Eyes treated with combination IVI/PDT demonstrated worse VA in year 2, with longer DFI and fewer NAI compared to IVI.


Choroidal Neovascularization Secondary To Ocular Histoplasmosis


Histoplasmosis, Neovascularization, Injection

For More Information:

Carl Noble

  • This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
    For questions regarding clinical studies at UC Health, contact us at or (513) 245-3417.